Rockwell Medical earns Fortune ranking. Rockwell Medical stock is valued at USD 31.0 million

Published on 10/14/2026 at 05:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rockwell Medical ranked No. 16 on Fortune's 2026 list on October 7, 2026. Rockwell Medical stock stood at USD 31.0 million on October 13, 2026.

Workplace ranking and operating progress

Rockwell Medical ranked No. 16 on Fortune's 2026 workplace list on October 7, 2026.
Second-quarter revenue reached USD 17.78 million, up 10.60 percent year over year.
Rockwell Medical stock had a USD 31.0 million market capitalization on October 13, 2026.

RMTI, US7743743004, Illustration mit AI erstellt.

Rockwell Medical ranked No. 16 on Fortune's 2026 Best Workplaces in Manufacturing and Production list on October 7, 2026, while Rockwell Medical stock carried a market capitalization of USD 31.0 million on October 13, 2026. The ranking gives the dialysis-products company a current corporate milestone as investors weigh its recent operating figures.

Fortune ranking adds visibility

According to Business Wire on October 7, 2026, Great Place to Work and Fortune placed Rockwell Medical No. 16 out of 50 companies in the small and medium category. The company has appeared on the list for three consecutive years, according to the release.

The award is tied to workforce conditions rather than a financial forecast. Rockwell Medical develops, manufactures and distributes hemodialysis products, including acid and bicarbonate concentrates, for dialysis providers worldwide, according to Rockwell Medical.

Revenue growth meets cash progress

Rockwell Medical's second-quarter 2026 revenue reached USD 17.78 million, an increase of 10.60 percent from USD 16.06 million in the comparable quarter, according to ToAlpha. The same quarterly summary listed an 18.20 percent gross margin and operating cash flow of USD 2.08 million.

The improvement was not yet equivalent to profitability. Finance data show a second-quarter net loss attributable to common shareholders of USD 1.17 million and diluted earnings per share of minus USD 0.34, compared with a USD 1.61 million loss and minus USD 0.40 diluted earnings per share in the first quarter of 2026. Revenue therefore improved sequentially by USD 0.44 million while the net loss narrowed by USD 0.43 million.

Market value and reporting date

Rockwell Medical's market capitalization stood at USD 31.0 million on October 13, 2026. The finance profile identifies the company as a Nasdaq-listed healthcare business in the specialty and generic drug manufacturers industry, with Mark Strobeck as chief executive officer.

ToAlpha lists November 11, 2026 as the next earnings date. That date places the third-quarter report ahead of the next major test of the company's revenue growth, gross margin and operating cash flow.